Most popular stories in October 2022

09-Nov-2022 - Last updated on 09-Nov-2022 at 11:20 GMT

Novo Nordisk, Sanofi, AstraZenec, Merck and Moderna, among others, feature in our round-up of top hitting stories last month. Photo Credit © GettyImages/PM Images

Related news

Once-weekly efanesoctocog alfa data shows ‘potential to transform the treatment landscape for hemophilia A’, says Sanofi
Sanofi announces boost to strategic venture fund
Moderna and CytomX partner up on mRNA-based conditionally activated therapeutics
Moderna to acquire OriCiro Genomics

Headlines

Biologics driving M&A as Agilent snaps up specialist BIOVECTRA for $925 million
Third Arc Bio raises $165M series A to develop biologics for cancer and immunology
Alvotech and Stada debut uzpruvo, the first ustekinumab biosimilar in Europe
Rona Therapeutics raises $35M in series A+ to advance metabolic siRNA therapeutics
Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal
Ionis announces positive early results for Angelman syndrome therapy
CordenPharma invests €900M in expanding peptide platform to meet GLP-1 drug demand
Top 5 CDMOs driving advanced therapies to market amid rising demand and challenges
Roche’s oral GLP-1 receptor agonist shows promising early weight loss results in phase 1
FDA delays approval of Novo Nordisk’s weekly insulin until requests are met
Lexeo’s gene therapy shows promising phase 1/2 results for Friedreich's ataxia cardiomyopathy
Rentschler opens advanced therapy production line as CDMO demand surges
HilleVax halts development of world’s most advanced norovirus vaccine after phase 2 failure

Most popular stories in October 2022

Related news

Follow us

Headlines

BioPharma-Reporter

Resources